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THE EFFECTS OF MINDFULNESS BASED STRESS REDUCTION ON BREAST  
 
CANCER SURVIVORS 
 
RUOHONG YAO ABSTRACT 	  
 Breast cancer is the most common type of cancer among women in the 
United States. Cancer diagnosis and treatment usually induce significant amount 
of psychological stress on patients, and breast cancer patients are especially 
susceptible to cancer-related distress. Chronic stress activates the hypothalamic-
pituitary-adrenal (HPA) and the sympathetic-adrenomedullary (SAM) axis, whose 
prolonged activation initiates physiological events harmful to the immune system 
and negatively influence cancer progression and recurrence. Therefore, it is 
important to identify and introduce effective cancer-related stress management 
programs and incorporate them into the standard cancer care routine besides 
conventional therapy.  
 Mindfulness-based stress reduction (MBSR) is an 8-week stress reduction 
program that has deep roots in ancient Buddhist practice and is used widely in 
clinics around the world nowadays. Is has been demonstrated to be effective in 
relieving stress and promoting well-being in a variety of populations, both clinical 
and nonclinical. And now it has started to be adapted into a complementary 
breast cancer therapy.  However, much of MBSR’s mechanism is still unknown, 
	  	   vi 
and no definite proof exists to show its efficacy in improving the negative 
psychological and physiological side effects of breast cancer treatment.  
This thesis summarizes and evaluates the current evidence of MBSR’s 
effectiveness in relieving psychological and physiological stress symptoms 
among breast cancer patients and survivors.  
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INTRODUCTION 	  
Breast cancer is the second most common cancer among women in the 
United States. In 2015, an estimated 231,780 new cases of invasive breast 
cancer will be diagnosed in woman (American Cancer Society (ACS), 2014). As 
a result of increased awareness, early detection through screening, and 
advances in medical treatment, deaths rates from breast cancer have been 
declining since 1989 and have led to increases in the number of breast cancer 
survivors. As of 2014, there are more than 2.8 million breast cancer survivors in 
the United States, including women under treatment and who have completed 
treatment. A cancer diagnosis is considered the most stressful and life-
threatening diagnosis a person can receive and it creates immediate 
psychosocial distress for the patient (Carlson et al., 2004). Reviews on the 
prevalence of depression among cancer patients suggest that the rates of 
depression symptoms are the third highest for breast cancer patients, exceeded 
only by patients with pancreatic cancer or head and neck cancer (Golden-Kreutz 
et al., 2004). Half of all breast cancer patients suffer from psychological distress 
related to the disease itself or side effects from the treatment and met the criteria 
of acute stress disorder (ASD) (McGarvey, 1998).   Such numbers necessitates 
the development for effective long-term stress-reduction coping strategies for 
breast cancer patients and survivors.  
Mindfulness-based stress reduction (MBSR) is a mindfulness-based 
meditation program used widely in clinical and nonclinical settings.  The practice 
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has its roots in the ancient Buddhist tradition in which practice of meditation aims 
to cultivate a state of mindfulness, defined as “a moment-to-moment non-
judgmental awareness” in the practitioners (Kabat-Zinn, 1985). MBSR was first 
introduced into hospital by Jon Kabat-Zinn at the University of Massachusetts 
Medical Hospital, and uses a combination of mindfulness-meditation, body 
scanning and simple yoga postures to help people cope with stress, distress, 
pain, and illness difficult to treat by conventional approaches. It also aims at 
increasing degrees of equanimity, wisdom, compassion and mindfulness in 
people (Matchim et al., 2011). MBSR has been the subject of increasing 
research interest, and it has been shown to have beneficial effects for various 
groups of clinical population, including cancer patients (Dobkin, 2008). However 
there is no direct link between MBSR practice and reduced stress level in breast 
cancer survivors. The objective of this study is to 1) to assess the effect of stress 
in breast cancer development and recurrence; and 2) to assess the effect of 
MBSR in reducing stress in breast cancer survivors.  
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PUBLISHED STUDIES  
 
Breast Cancer 
The prevalence, incidence and lifetime risk of breast cancer indicates the 
importance of conducting studies in the area of breast cancer treatment and 
patient care. Breast cancer is the most commonly diagnosed cancer in women in 
the United States, accounting for approximately 30% of all incident cancers 
among this group. It is also the second leading cause of cancer death in women 
in the United States, exceeded only by lung cancer (ACS, 2014). In 2015, it is 
estimated that there will be 231,840 new cases of breast cancer and an 
estimated 40,290 people will die of the disease. Approximately 1 out of 8 women 
will be diagnosed with breast cancer at some point in their lifetime. In 2015, there 
are an estimate 2.8 million women in total living with breast cancer in the United 
States, including women currently being treated and who have finished 
treatment.  
 
Risk Factors for Breast Cancer  
 Many risk factors for the development of breast cancer have been 
identified (Freedman et al., 2005). Many of the factors cannot be modified, 
including gender, age, ethnicity, family history, and genetics. Breast cancer 
incidence rises sharply with age and is most common with middle age and older 
women. The rate of increase in breast cancer incidence also increases with age, 
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but slows substantially after menopause, when the level of endogenous 
hormones declines. Although these factors cannot be changed, knowing their 
existence may help detect breast cancer earlier by regular self-examination and 
screening. Screening mammography has been shown to be effective in detecting 
breast cancer at early stages and decreasing mortality rate (Fracheboud et al., 
2004). 
Family history is recognized as a strong risk factor for the development of 
breast cancer, although the majority of the cases are sporadic and without any 
known family history. A woman’s risk of developing breast cancer doubles if her 
first-degree relative (mother, sister, or daughter) has been diagnosed with the 
disease (American Cancer Society, 2014). Familial breast cancers with known 
germline genetic mutations account for 5% to 10% of all breast cancer cases. 
Some high-penetrance genes include BRCA1, BRCA2, TP53, PTEN, STK11, 
and CDH11 (Campeau, 2008). Of these, mutations in the tumor suppressor 
genes BRCA1 and BRCA2 are the most prominent, accounting for 20% to 25% 
of familial breast cancer and 5% to 10% of all breast cancers (Narod, 2010). Both 
BRCA1 and BRCA2 mediate cellular response to DNA damage and mutations in 
either gene increases the lifetime risk for the development of breast cancer by 
60% to 80% (Matsen et al., 2013). BRCA1 and BRCA2 are also associated with 
other cancer types, including ovarian cancer. BRCA1 is more strongly associated 
with ovarian caner, while BRCA2 is more strongly associated with breast cancer 
in male and pancreatic cancer (Wickerham, 2010). Breast cancer arising from 
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germline mutations in BRCA1 and BRCA2 tends to develop at a younger age 
than their non-familial counterparts, and the majority of BRCA1-associated cases 
are triple-negative, both are independent indicators of a poor prognosis (Anders 
et al., 2008). The BRCA mutation carriers also have a significant higher 5-year 
and 10-year recurrence rate (11-20% and 25-27%, respectively) than individuals 
without a BRCA mutation (1-3% and 1-9%, respectively) (Trainer, 2010). 
Discovery of BRCA mutations enables genetic testing that can help target 
unaffected women at high risk for primary prevention and close surveillance. 
Genetic testing available at the time of diagnosis helps decide better tailored 
treatment for patients because the response of BRCA- associated cancers to 
treatment is related to the underlying genetic defect and can be different from 
other cancers with similar histological characteristics (Figure 1a).  
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Figure 1. Breast Cancer Incidence and Mortality Rate by Age. Data from Surveillance, 
Epidemiology, and End Results (SEER) Program. 
 
Some risk factors are environmental and life style-related, including 
bodyweight, alcohol consumption, physical activity, pregnancy, use of birth 
control, exposure to diethylstilbestrol (DES) and hormonal therapy after 
menopause (Vijayvergia & Denlinger, 2015). These factors are modifiable and 
thus have important implications in planning breast cancer prevention strategies.  
 
Types of Breast Cancer and Stages 
Breast cancer is not a single disease, but a highly heterogeneous one. 
There are multiple subtypes of breast cancer that have different etiology and 
mechanism, respond to different types of treatments, and can be more or less 
invasive. Historically, breast cancer has been classified by a histological typing 
and grading system based on the site of origin of the tumor, spreading of tumor 
cells, and distinct morphological features of the abnormal cells and tissues. 
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Human breasts primarily consist of connective tissue supporting the mammary 
glands. The secretary unit of the gland is organized into 15 to 20 lobules, which 
in turn consist of smaller structures, lobes.  Lobes are connected through a 
network of ducts, which eventually merge and exit skin through nipple. Human 
breasts are highly vascularized with an extensive network of blood vessels, 
lymphatic vessels and nodes, and nerves. The lymphatic drainage of the breast 
primarily goes into the axially lymph nodes, which is of special importance in the 
context of breast cancer because lymph nodes are prominently involved in 
cancer metastasis in advanced cases. Most breast cancer develops at the 
terminal ductal lobular unit, and the most common noninvasive breast cancers 
are ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). Most 
breast cancer starts as DCIS and approximately 20% of them are confined to the 
ducts. If detected early, DCIS has a high likelihood of being cured (Vatovec et al., 
2014).  In very rare cases (1% to 4% of all breast cancer cases), cancer cells can 
spread to the dermis of the nipple in a condition called Paget’s disease, and it is 
considered benign if no other invasive tumor is present (Chen, 2006). If DCIS 
begin to spread to surrounding tissues or invade adjacent lobes, ducts or connect 
tissue it becomes invasive ductal carcinoma (IDC). There exist a large number of 
invasive breast cancer subtypes, of which IDC is the most common type and 
comprises approximately 80% of all invasive breast cancer cases (Matsen, 
2013). In more advanced conditions, cancer cells may spread through lymph 
nodes and blood to distant parts of the body, most often the bones, lungs, liver, 
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or brains. The Nottingham histologic grading system of breast cancer grades a 
tumor based on three criteria—tubular formation, nuclear feature, and mitotic 
activity. The grade of a tumor is representative of its potential invasiveness, with 
low-grade tumors being less invasive and more likely to have better prognosis 
than high-grade tumors (Elston & Ellis, 1991). The grading system is augmented 
with a clinical staging system, the TNM system, which takes into consideration 
tumor size (T), lymph node involvement (N), and distant metastasis (M) to 
provide a more complete picture of tumor development. The systems work by 
assessing the T, N, M, categories of a tumor and combining the information in an 
aggregate scoring system that assigns a numerical stage number 0 to IV to a 
tumor (Table 1). While Stage 0 is the least advanced, in situ cancers that are 
confined to the layer of cells where the cancer develops (DCIS and LCIS), Stage 
IV is the most advanced tumor that has spread to distant tissues outside the 
breast.  The staging system is a well-validated and important prognostic tool in 
clinical settings because it provides a more accurate prognosis for the disease 
and helps determine treatment options appropriate for the patient. When 
planning and conducting a clinical research study, it is important to know the 
tumor stage and the type of treatment a patient has received to reduce bias when 
selecting a cohort. 
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Table 1. 5-year Survival Rate by Stage.  
Stage of Cancer 5-year Relative Survival 
Rate* 
0 100% 
I 100% 
II 93% 
III 72% 
IV 22% 
*Data from American Cancer Society.  
 
Breast Cancer Treatment  
 The treatment of breast cancer is multidisciplinary and can include local 
and systemic therapy. Local therapy aims to remove tumor cells without affecting 
the rest of the body, and common approaches of local therapy includes surgery 
and radiation. Systemic therapy aims to treat cancer cells that have spread 
outside the breasts and is usually used as adjuvant treatment following local 
therapy to reduce the risk of recurrence. Chemotherapy and hormone therapy 
are commonly used systemic therapy. Many factors, including hormone receptor 
status, tumor stage and histology, and genetic profile are taken into account 
when choosing the right type and sequence of therapies for a patient.  
 Clinically, breast cancer can be categorized into three basic therapeutic 
groups: the estrogen receptor (ER) positive group, the HER-2/neu gene amplified 
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group, and the triple negative breast cancer (TNBC) group (Perou et al., 2000). 
The ER-positive breast cancers are the most prevalent. Expression of ER in 
breast cancer cell, whether or not with co-expression of progesterone receptor 
(PR), makes good candidates for hormonal anti-estrogen therapies, since these 
cancers need supplies of estrogen to grow. The most widely used drugs in this 
group of treatment are ER-blockage tamoxifen and aromatase inhibitors, the 
latter only used in postmenopausal women whose major source of estrogen is 
from the aromatase pathway. They stop the growth of cancer cells by either 
suppressing estrogen production or competing with estrogen for ER receptors on 
breast cancer cells. 5 years of anti-estrogen therapy with either tamoxifen or 
aromatase inhibitors has been shown to reduce breast cancer recurrence and 
mortality in early and advanced stage patients (Davies et al., 2013). Tamoxifen 
also proves beneficial to breast cancer prevention by lowering the risk of 
developing cancer in high-risk women with BRCA mutations (Gronwald et al., 
2006).  
The HER-2/neu amplified group has exceptionally high level of expressed 
in breast tissues. Amplification of HER-2/neu is associated with a poor prognosis, 
higher rates of recurrence and relative resistance to hormonal therapy (Tandon 
et al., 1989). Her-2 target therapy using monoclonal antibody against HER-2/neu, 
trastuzumab, improves outcomes in those patients (Paik et al., 2008). The last 
group of breast cancers TNBC is defined by the lack of ER and PR expression 
and the absence of HER2 /neu overexpression. It is one of the most aggressive 
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types of breast cancer, with a higher probability of metastasis, risk of recurrence 
and mortality from advanced disease compared with other breast cancer types 
(Tamao et al., 2015). TNBC confers resistance to hormonal therapy and is only 
treated with chemotherapy. Inhibitor of Poly (ADP-ribose) polymerase (PARP), 
an enzyme involved in repairing DNA double strand, is emerging as a potential 
treatment for both TNBC and BRAC-related cancers (Hastak et al., 2010).  
 
Trend in Epidemiology of Breast Cancer  
 The incidence of breast cancer has increased for many decades since 
1975 due to a combination of increased early detection through mammography 
screening and use of menopausal hormonal replacement therapy (Harding et al., 
2015). The incidence rate dropped abruptly during early 2000 and has been 
stable over the past decade. Many factors contribution to the changes in 
incidence rate over time, including changes in environmental and behavioral 
patterns, improved screening methods and changes in screening behaviors. 
Mortality rates have declined during the past few decades, but have not changed 
significantly since 2002. However an overall steady improvement on 5-year 
survival rates has been achieved during the past few decades. Overall changes 
in incidence rates and 5-year survival rates suggest a growing number of breast 
cancer survivors, many of them are undergoing transition to post-treatment life.  
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 Year  1975  1980  1985  1990  1995  1999  2003  2007
5-Year 
Relative 
Survival 
75.2% 74.8% 78.4% 84.6% 86.8% 89.6% 89.7% 91.0% 
Figure 2. Trend in Breast Cancer Rates from 1975 to 2012. Data from SEER. 	  	  
Stress and Cancer 
 
Defining Stress 
Although stress is a common subject in our daily conversation, its 
meaning is somehow ambiguous. Stress is predominately used in the negative 
sense of ‘distress’, as being in a chronic state of physical or mental suffering, but 
also, in some cases, it might refer to a situation of challenge that induces a 
feeling of exhilaration and excitement. In 1936, Hans Selye first defined stress as 
the “non-specific response of the body to any demand for change” (Selye, 1975). 
This definition sees a stimulus, or a stressor, as a challenge to homeostasis, the 
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body’s maintenance of its important physical parameters within a certain range to 
sustain viability, and a body’s response to stress the reactions of the 
neurobiological systems that help preserve viability through change, or allostasis 
(McEwen & Seeman, 1999). A more integrated definition states that stress is a 
sequence of events, consisting of a stressor, perception of stress in the brain, 
and biological responses elicited in the body (Dhabhar, 2014). A stressor can be 
a physical one such as bacterial infection or toxin, or a psychological one such as 
depression, chronic sleep disruption, or traumatic life events. The brain is the 
master for the perception and interpretation of stress, and also a target of its 
effect (Gunnar & Quevedo, 2007). The outcome of the interpretation is 
communicated through a cascade of events which then triggers stress responses 
in the peripheral nervous system and across a variety of organ systems. To 
summarize, stress is a complex process involving environmental and 
psychological factors, and it initiates a cascade of physiological responses that 
have significant implications on human health.  
  
Physiology of stress response  
 The stress response in humans is mainly mediated through two distinct 
but interrelated systems, the sympathetic-adrenomedullary (SAM) axis and the 
limbic hypothalamic-pituitary-adrenocortical (HPA) axis. Of importance is the 
release of stress hormones. The SAM axis is part of the sympathetic division of 
the autonomic nervous system (ANS), and upon activation it releases 
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catecholamines, principally adrenaline (epinephrine) and norepinephrine from 
sympathetic neurons and the adrenal medulla. The SAM axis is involved in acute 
stress response, and increased adrenaline level prepares the body for the fight-
or-flight response. Circulating adrenaline and norepinephrine bind to 
adrenoreceptors in multiple targets, and some of the downstream effects include 
increase in heart rate and cardiac output, increase in respiratory rate, increase in 
gluconeogenesis in the liver, vasodilatation in muscles, and inhibition on 
digestive and reproduction system (Charmandari et al, 2005). In terms of 
evolution, acute stress response is considered a natural’s mechanism for 
survival, since it results in increased energy recourses for defensive response, 
and psychologically it increases vigilance, focused attention, and immediate 
arousal (Charmandari et al, 2005).  
The HPA axis is mediated by production of corticotrophin-releasing 
hormone (CRH) and arginine vasopressin (AVP) in the hypothalamus. CRH and 
AVP then activate secretion of pituitary hormones such as adrenocorticotropic 
hormone (ACTH). ACTH induces downstream production and release of steroid 
hormone glucocorticoid (cortisol in human) from the adrenal cortex. Cortisol is 
the major effector of HPA axis, and it regulates a broad range of effects including 
anti-inflammation responses and metabolism of carbohydrates, fats, and proteins 
(Glaser & Kiecolt-Glaser, 2005). The way it interacts with target cells is through 
binding to receptors inside the cells and initiating transcription of genes that have 
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glucocorticoid-responsive elements. Because it involves target gene expression, 
effects of cortisol take longer to produce and last longer.  
  
 
Figure 3. Stress systems. Adapted from Antoni et al., 2006.  
 
Stress and the Immune System  
Stress has different effects on the human immune system depending on 
its duration. Short-term stress that lasts less that 2 hours may enhance some 
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aspects of immune functions, such as migration of leukocytes, most prominently 
natural killer cells (NK cells) and granulocytes, from lymphoid organs (spleen) to 
the peripheral blood and the skin (Dhabhar et al, 1995).  The migration is 
mediated by stress-induced release of adrenaline and cortisol interacting with 
their receptors at the cell surface of lymphocytes, and it is hypothesized that such 
a redistribution of lymphocytes is beneficial because it significantly enhances skin 
immunity and wound healing (Dhabhar, 2014). In addition, short-term stress also 
enhances secondary immune response at the time of re-exposure to antigen by 
increasing the numbers of memory and effector helper T cells (Dhabhar & 
McEwen, 1997).  
 In contrast, chronic stress has been shown to suppress or dysregulate 
certain aspects of immune function through prolonged activation of SAM and 
HPA axis. Chronic stress induces a decrease in leukocyte mobilization from the 
blood to other body compartments, accompanied by a decrease in skin immunity. 
Chronic stress also suppress other immune parameters include antibody 
production, leukocyte proliferation, and number and activity of NK cells (Antoni, 
2006). Of special interest are the NK cells because they are involved in tumor 
suppression. Low NK cell number is a prognostic factor for early breast cancer 
mortality and low NK cell cytotoxicity is predictive of a poor breast cancer 
outcome (Sephton et al, 2000). More specially, high levels of psychological 
stress are correlated with low NK cell cytotoxicity in ovarian cancer (Lutgendorf et 
	  17 
al, 2005), while positive social support is correlated with increased NK cell 
cytotoxicity in breast cancer (Levy, 1990) 
 Another mechanism through which chronic stress suppresses immune 
function is by inducing premature immune cell aging and senescence. Aging at 
the cellular level is usually measured as telomere length or telomerase activity. 
Telomeres are DNA-protein complexes at the ends of chromosomes that protect 
genome stability and shorten with each cell division cycle. Telomerase is an anti-
aging enzyme that helps prevent telomere shortening by adding short nucleotide 
repeats to the telomere regions. The rate of telomere shortening is believed to 
reflect physical wellness and individuals with shorter telomeres are more 
susceptible to infection and mortality due to diseases like cardiovascular disease 
(Epel et al, 2006).  Researches have shown links between stress and 
accelerated aging at cellular level. More specifically, women with high chronic 
stress levels have significantly shorter telomeres and lower telomerase activity in 
their blood lymphocytes compared to women with low chronic stress levels (Epel 
et al, 2004). In this way, chronic stress induced acceleration of immune cell aging 
can have deleterious effects on the human immune system and can increase the 
risk of developing age-related diseases.  
 Chronic stress also disrupts the body’s mechanism of regulating 
inflammation response and production of pro-inflammatory cytokines. Although 
acute inflammation is central to survival by providing the first line of defense 
against injury, chronic inflammation that goes on for days might be detrimental to 
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health. Increases in adrenaline and cortisol levels may increase the expression of 
pro-inflammatory cytokines such of interleukin-6 (IL-6) and tumor necrosis factor 
alpha (TNFα). IL-6 has been linked to diseases including cardiovascular disease, 
arthritis, type 2 diabetes, and particularly, cancer (Harris et al, 1999). It is shown 
that IL-6 and TNF-α promote tumor initiation by inducing DNA damage and 
inhibiting DNA repair through the generation of oxidative species (Reuter et al, 
2010). IL-6 and TNF-α also support tumor growth by preventing apoptosis in 
tumor cells and promoting angiogenesis (Balkwill & Mantovani, 2012).  
 
Psychological Stress 
Psychological stress response ensues when an event or environmental 
demand exceeds an individual’s perceived ability to cope. When making 
connections between psychological stress and disease risk, the psychological 
tradition focuses on individuals’ perceived stress level and their affective 
response. Perceived stress is a subjective evaluation of the degree to which life 
events are perceived as stressful. It is usually measured by self-report surveys in 
which participants are asked to rate their perceptions of stress on a scale by 
answering certain questions, or they may be questioned by researchers to 
assess the number and type of stressful life changes happened during a period 
of time. The most widely used instruments to assess perceived stress level are 
the Perceived Stress Scale (Cohen, 1983). The affective responses to 
psychological stress, which typically includes negative thoughts, emotion, are 
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usually assessed through changes in behavioral patterns including sleep 
disturbance, and symptoms of general distress, anxiety, or depression. Measure 
of perceived stress is augmented by measure of objective biomarkers of stress 
including cortisol level and immune markers. These two factors combined show a 
more accurate and comprehensive picture of how chronic stress influence 
disease risk.  
 
Biomarkers of Stress 
 Besides psychological testing on perceived stress, a set of physical 
parameters is routinely used to measure objective stress level. These 
parameters are categorized into two types: primary mediators of stress, and 
secondary outcome measures, which are the consequences of action of primary 
mediators.  
 The end products of SAM axis and HPA axis activation are easily 
measurable in blood, saliva, and urine. Salivary cortisol level is the most 
commonly used biomarker in stress studies due to its low-invasiveness and ease 
of obtaining. The secretion pattern of cortisol has been well studied in normal and 
pathological conditions (Kalpakjian et al., 2010). Under normal or unstressed 
condition, secretion of cortisol shows distinct circadian rhythmicity, characterized 
by a peak concentration in early morning hours, followed by a progressive 
decline throughout the day, and ended with an abrupt elevation during the first 
few hours of sleep. This diurnal secretion of cortisol is influenced by presence of 
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stress and is believed to reflect psychological and physical health (Ross, 2014).  
The peak in cortisol level immediately after waking is called the awakening 
cortisol response (ARC). ARC is known to be stable in each individual across 
days, but may be blunted or flattened due to high stress or poor health (Gunnar & 
Vazquez, 2001). It is shown that breast cancer patients who have a flattened 
daily cortisol secretion level have accelerated disease progression and early 
mortality (Touitou et al., 1996). Considerable attention has been given to account 
for inter-individual and intra-individual variances at different measuring times. 
Another method to measure HPA axis activation is by the level of 
dehydroepiandrosterone (DHEA), which is also an adrenal hormone works by 
countering the actions of cortisol. Decline in DHEA is associated with stress-
related symptoms since it leaves the action of cortisol less regulated.  Other 
common biomarkers for HPA activation include components of the immune 
system such as the count and activity of NK cells, certain cytokines such as 
TNFα, IL-6, IL-1, and interferon gamma (IFNγ), and telomerase activity (McEwen, 
2002).  
 Measurements of secondary physiological outcomes provide 
complimentary information to those of primary mediators like cortisol and 
inflammatory cytokines. Commonly measured outcomes include blood pressure 
and heart rate, which indicate changes in the cardiovascular system. Level of 
metabolism, cholesterol, and adipose tissue deposition are also assessed 
because they are thought to be influenced by increased cortisol activity.  
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Table 2: Biomarkers of chronic stress  
Some primary mediators and secondary outcomes* 
Primary mediators 
Elevated levels of inflammatory cytokines  
Elevated and flattened diurnal cortisol rhythms 
Elevated overnight urinary cortisol  
Low DHEA: cortisol ratio 
Elevated levels of overnight urinary catecholamines 
Abnormal insulin levels (also assessed indirectly as abnormal glucose levels 
Secondary outcomes 
Brain: atrophy of brain regions, cognitive impairment  
Cardiovascular: atherosclerosis, left-ventricular hypertrophy, clotting actors, 
homocysteine, and oxidative stress markers 
Immune system: impaired wound healing, retarded immunization response, 
suppressed delayed-type hypersensitivity, chronic pain and fatigue reflecting 
imbalance of immune system regulators in the CNS 
Metabolic: glycosylated hemoglobin, HDL: LDL, cholesterol, abdominal fat 
deposition (as measured by the waist-hip ratio), bone mineral density 
*Adapted from McEwen, 2002 
 
Effects of Stress-related Factors on Cancer Initiation and Progression 
 Psychological factors have long been believed to influence the outcome of 
human diseases, including cancer. As early as AD 200, Glan observed that 
“melancholic women were more susceptible to ‘swellings’ of the breasts than 
were sanguine women” (Reiche, 2004). In the past 30 years, increasing clinical 
evidence suggest chronic stress contributes to cancer initiation, progression and 
metastasis.  
Overall, studies linking stress and cancer incidence are mixed at best, 
possibly due to the difficulties in making accurate associations between stressor 
and disease onset across long year gaps. For example, a study in 2000 found 
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that women who have experienced extreme stress and are without positive social 
support have a nine-fold increase in risk of developing breast cancer (Price et al., 
2001). A US cohort study found a similar relationship between maternal death in 
childhood and breast cancer in adulthood (Jacobs, 2000). These results are not 
strong indicators of a relationship between stress and cancer initiation.  
It is generally acknowledged that stress plays more important a role in 
cancer progression and recurrence than initial onset of the disease. A study 
showed that women with breast cancer who had flattened ACR or abnormal 
diurnal changes in cortisol level had early mortality (Carlson, 2004). And in 
general, cancer patients who are under distress and tend to use negative coping 
styles have accelerated disease progression and higher recurrence rate (Reiche, 
2004).  By contrast, positive social support optimism predicts longer survival and 
better prognosis (Allison et al., 2003). Recent studies have started to understand 
the mechanism of action of stress. One theory proposes that activation of CNS 
and ANS by stress and the subsequent release of stress hormones change the 
tumor microenvironment in way that favors tumor-cell growth and migration 
(Antoni et al, 2006).  Stress may also compromises DNA repair mechanism 
(Fischman et al., 1996), or enhance angiogenesis by promoting tumor production 
of vascular endothelial growth factor (VEGF) (Lutgendorf et al., 2002).  Figure 4 
illustrates the effects of stress factors on tumor microenvironments.  
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Figure 4. Stress and Cancer progression. Adapted from Antoni et al., 2006.  
 
 
	  24 
Stress in Breast Cancer Patients 
 A cancer diagnosis can be the most stressful and life-threatening event a 
person can experience, regardless of the prognosis, and the feeling of stress 
may in turn influence the disease trajectory. Based on gender, women are more 
susceptible to acute stress disorder (ASD) following diagnosis of cancer than 
men (McGarvey et al, 1998). It has also been shown that women undergoing a 
biopsy for breast cancer diagnosis have higher perceive stress and anxiety, 
accompanied by reduced NK cell activity and cytokine dysregulation  
(Witek-Janusek et al, 2007). Women who undergo breast cancer treatment 
experience greater emotional distress and mood disturbance, worry about 
prognosis and recurrence, and have decreased sense of well being (Boehmke & 
Dickerson, 2006). It is estimated that 50% of breast cancer patients meet the 
criteria for depression, 19% for post-traumatic stress disorder, and 33% for ASD 
(French-Rosas et al, 2011). The most common symptoms affecting breast cancer 
survivors are fatigue, insomnia, depression, cognitive dysfunction, and 
lymphedema (Pinto & Azambuja, 2011). Traumatic stress symptoms significantly 
impair patients’ quality of life and their ability to adjust to post-treatment life, and 
affect the disease outcome and recurrence rate.  
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Mindfulness-based stress reduction 
 
 
 Untreated cancer-related stress has huge negative impacts on all aspects 
of a patient’s life, decreases psychological and physical well being, lowers quality 
of life, and even impacts disease outcome and recurrence. Therefore 
management of stress in patients living with or beyond cancer is of significant 
importance. In addition to conventional cognitive behavioral interventions, the 
use of complementary and alternative (CAM) therapies among cancer patients 
has become popular. It is estimated that 64% to 86% of women with breast 
cancer used some form of CAM to cope with psychological distress (Lengacher, 
2002). Some common forms of CAM, including acupuncture and music therapy, 
showed positive effects in reducing pain and vomiting in breast cancer patients 
(Alferi et al., 2001; Beck, 1991).  
 Over recent years, mindfulness-based therapies have become a more 
popular form of CAM used in conjunction with conventional treatment to reduce 
psychological and physical symptoms related to cancer or cancer treatment in 
women with breast cancer.  
The idea of mindfulness originated in the ancient Buddhist Theravada 
tradition and it is viewed as the core of Buddhist teachings. Mindfulness is 
defined in the Buddhist context as ‘the clear and single-minded awareness of 
what actually happened to us and in us at the successive moments of perception’ 
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(Bonadonna, 2003). The essence of mindfulness is a “moment-to-moment 
nonjudgmental awareness” (Kabat-Zinn, 1994). In this sense, mindfulness is a 
way of paying attention. Usually by concentrating attention to a sound, object, 
breath, visualization, or movement, the practitioner increases awareness of the 
deep interconnection of mind and body, and consciously brings awareness to the 
experience and observation at the present moment, without making judgments 
about it, and without thinking about the past and the future. The ability to direct 
attention in this way can be developed through the practice of meditation, and in 
order to build and maintain mindfulness, an individual needs to practice a certain 
set of meditation skills regularly with persistence (Matchim, 2007). The continued 
practice of mindfulness meditation is thought to elicit joy and end suffering in the 
Buddhist tradition. Also in this tradition, mindfulness meditation is not as much a 
specific technique for stress reduction but a way of being to be practiced 
regardless of the disease state. Promoting relaxation and spiritual growth are 
seen as some of the positive side effects for long-term practitioners.  
In contrast to the tradition of cognitive behavioral therapy, mindfulness 
meditation is not goal-oriented and does not encourage practitioners to challenge 
their thoughts or alter their way of thinking. And unlike traditional meditation 
forms, mindfulness meditation does not require practitioners to free their mind of 
all thoughts and maintain a state of mind that is no-self. The core of mindfulness 
meditation is to experience, observe, and accept any event happened around 
and thought or sensation that naturally come into consciousness at a particular 
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moment, and at the same time to maintain a neutral, non-interpretive and 
nonjudgmental perspective. Practitioners usually sit in a comfortable position in 
silence, and are taught to focus their attention on a particular object or a process, 
like a sound, a breathing rhythm, a visualization, or movement. Using this object 
or process of focus as an anchor, practitioners scan their thoughts in an open 
mental field while staying consciously aware of what is happening inside and 
outside their body. When sensations and emotions arise, they are taught to 
experience and describe them nonjudgmentally. When practitioners notice that 
the mind has wandered into memories and fantasies, or starts engaging in the 
process of rumination or analysis, they note the contents of their thoughts briefly 
and then redirect their attention to the object or process of focus (Ott et al., 
2006). In this way, practitioners also learn effective ways of handling emotions by 
bringing awareness to their experience, as apposed to being caught up in an 
‘automatic pilot’ state in which they just react automatically to environmental 
stimuli when they are feeling stressed (Zainal et al, 2013).  
Mindfulness meditation was first incorporated into clinical intervention by 
Dr. Jon Kabat-Zinn at the University of Massachusetts Medical Center in 1979. 
Initially developed as a psychoeducational training program for chronic pain 
patients and stress-related conditions (Kabat-Zinn, 1994), mindfulness-based 
stress reduction (MBSR) is a highly structured group program usually conducted 
as an 8- to 10-week course for as many as 30 participants who meet weekly for 
mindfulness meditation techniques, yoga exercises, and group discussions of 
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stress and coping. The major goal of the intervention program is to train 
participants to monitor and self-regulate their mood disturbances and reduce 
perceived stress when confronted with stressful events. Participants take part in 
weekly sessions that typically last for 1 to 1.5 hours plus one silent retreat 
session. During class, participants are taught the fundamentals of mindfulness 
meditation, information about the psychophysiology of stress response, and 
experiential mindfulness practice. Participants also get plenty of supportive 
interaction between group members including group discussions about 
progresses of their at home practices, challenges and barriers they experience, 
and application of mindfulness in daily situation. During the first class, 
participants also receive educational materials like CDs or DVDs to be used to 
support their home practice sessions. Each participant is expected to practice 45 
minutes at home on a daily basis to be considered compliant with the intervention 
routine.  
The mindfulness meditation techniques taught in MBSR include sitting 
meditation, body scan, Hatha yoga, and walking meditation (Kabat-Zinn, 1985). 
These practices are introduced gradually in intensity and strength, and are 
hypothesized to lead to a gradual transformation on the practitioner’s level of 
mindfulness. Sitting meditation involves bringing awareness to bodily sensations, 
initially with a focus on the physical sensation of breathing. Once the practitioner 
learn how to pay attention to the breathing process and continue to do it, they will 
be able to breath more fully and easily, which is thought to alleviate stress 
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response and elicit relaxation response in the body. After learning to focus on 
breath awareness, they may proceed to focus on physical sensation of pain in 
order to cultivate a realization that pains are not constant but change from 
moment to moment, and they will learn to separate the physical sensation of 
pains apart from its negative connotation such as cancer progression. The body 
scan is another mindfulness meditation technique consisting of gradually shifting 
one’s focus through various regions of the body from head to toe. This practice 
aims to develop a deeper appreciation for the subtle changes happening inside 
the body from time to time, and to foster deeper mind-body awareness. Hatha 
yoga, or mindfulness movement, involves various postures and gentle stretches 
to increase awareness of body in motion, and promote balance of mind and 
strength in musculoskeletal system. The last technique, walking meditation, 
which is similar to Hatha Yoga, aims to increases awareness of body in motion, 
especially in walking activities. Learning and practicing these mindfulness 
meditation techniques are instilled in the 8-week course along with homework 
assignments and support group activities.  
MBSR has been shown to be beneficial to both non-clinical and clinical 
populations (Khoury et al., 2015; Gotink et al., 2015). It is most notable for its 
efficiency for problems like chronic pain (Kabat-Zinn, 1982), anxiety disorder 
(Miller et al., 1995), and hypertension (Schneider et al., 1995). Given that 
emotional distress after cancer diagnosis is common, and cancer patients have a 
strong desire to be active and take initiative in personal care, it is logical to study 
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the benefits of MBSR on cancer populations. Carlson et al conducted a 
prospective study with a sample of 59 patients with early stage breast and 
prostate cancer in 2003 and reported significant improvements in pre- to post-
treatment in sleep quality and stress symptoms following MBSR intervention. 
Additionally they evaluated immune outcomes including lymphocytes counts and 
cytokine production. While they didn’t observe significant changes in numbers of 
any of the lymphocyte subtypes (NK, T, or B cells), there were statistically 
significant changes in some of the cytokines assessed, IL-4 and IL-10. They 
concluded that the overall pattern of immune changes is suggestive of a shift 
away from pro-inflammatory to anti-inflammatory environment (Carlson et al, 
2003). A continuing study in 2004 reported additional results of the 
neuroendocrine outcomes of salivary cortisol, serum DHEAS, and salivary 
melatonin from the same sample of breast and prostate cancer patients. This 
study confirmed previous findings of improvement in stress symptoms, health 
behaviors, and overall quality of life, but observed no associated changes in 
stress hormones level. Although the overall cortisol, DHEAS, and melatonin 
levels did not change significantly pre-to post-intervention, diurnal cortisol 
secretion patterns demonstrated attenuation of more extreme values, indicating a 
shift towards a possibly healthier HPA axis functioning. DHEAS level also 
demonstrated gender-specific changes consistent with healthier patterns 
(Carlson et al, 2004). These studies are among the first to demonstrate the 
potential effects of MBSR as a cancer intervention therapy and they showed its 
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potential benefits on immune and neuroendocrine profile. But the results are not 
generalizable due to their same sample size and lack of control groups.  To study 
effects of MBSR on breast cancer, it is important to study a homogenous groups 
of female breast cancer patients stratified by cancer stage and treatment types, 
since some stress responses are gender-based and patients may show 
differential responses to the same treatment depending on the point at which 
they are in the disease trajectory.  
 
 
Effects of MBSR on reducing stress in Breast Cancer Survivors 
 
 
Psychological outcome  
 Most of the studies on the effects of MBSR in reducing stress symptoms in 
breast cancer patients have focused on psychological outcomes, including 
perceived stress level, depression, anxiety, cognitive function, quality of life, and 
fear of recurrence. However researchers have used different measuring scales, 
study designs, and even different forms of MBSR practice, making it difficult to 
compare and interpret their results.   
In 2011, Matchim et al. preformed a meta-study summarizing the 
outcomes from previous studies on MBSR practice and breast cancer women 
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(Matchim et al., 2011). Below is the chart showing the lists of studies he included 
and their results on psychological outcomes (Table 3).  
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Table 3. Psychological Improvements following MBSR program in Breast Cancer 
Survivors.  
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Individual symptoms of psychological disturbance in breast cancer 
patients are not isolated phenomena, but are interrelated and may stem from the 
same sources or mediators. Fear of recurrence (FOR) is an established source 
of emotional distress among breast cancer patients and survivors. FOR is 
triggered by antecedent of physical symptoms like pain and rumination on those 
perceived risk result in psychological distress, decreased quality of lie, functional 
impairments and fatigue (Lengacher et al., 2014). Considering how FOR arises in 
patients, an MBSR program that focuses on paying attention to body sensations 
without thinking about its negative implications may help reduce intrusive 
thoughts, reduce FOR, and thereby reduce other FOR-related symptoms of 
psychological disturbance. Lengacher et al. studied FOR as a mediator of stress 
symptoms and how it is affected by MBSR practice. 84 early stage breast cancer 
patients were randomized into an MBSR practice group and a usual care group 
and were followed for 8 weeks from entry into the study to 2 weeks after the 
completion of MBSR. Outcome measures included perceived stress, depression, 
anxiety, quality of life, physical functioning, and FOR assessed by the Concerns 
about Recurrence Scale. As hypothesized, they found participants in the MBSR 
group were more likely to experience favorable reductions in FOR, improved 
psychological state and physical functioning compared to those in the usual care 
group. In the graph below, Lengacher et al hypothesized a biobehavioral logical 
model that postulates FOR might be the mediator of MBSR program to positive 
changes in psychological and physical symptoms.  
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Figure 5. Hypothesized biobehaviroal model: FOR as a result of participating in the MBSR 
program and mediate a range of positives changes. Adapted from Lengacher et al., 2014.  
 
  
The prevalence of sleep disturbance is high among cancer patients, and 
symptoms may persist many years after the end of treatment. The prevalence of 
clinically diagnosed insomnia is especially high among breast cancer survivors, 
which is about 68% (Palesh et al., 2010).  Sleep difficulties are usually 
associated with high levels of chronic stress, and may contribute to fatigue and 
poorer treatment outcome (Vargas et al., 2013). As part of a large randomized 
clinical trial (NCT01177124) on the effect of MBSR on psychological and physical 
symptoms in breast cancer survivors, Lengacher et al. reported the effects of 
MBSR on objective and subject sleep parameters in 79 breast cancer survivors 
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with a previous stage 0-III cancer diagnoses. Participants were randomized into 
either a 6-week modified MBSR program group or a usual care group, and 
measures were taken at entry into the study and at follow up 12 weeks after 
completion of program. (Lengacher et al, 2015). They found significant 
improvements in the subject sleep parameters from 6 to 12 weeks in the MBSR 
group using actigraphy measures of sleep efficiency (percentage of time in bed 
spent sleeping) and number of waking bouts, with a moderate magnitude of 
differences between groups. Comparable improvements in objective sleep 
parameters using sleep diaries and participants’ recall of sleep pattern and 
behaviors were not observed during the 12-week follow-up, though results seem 
to be in the trend of improving after MBSR intervention. These trends were in 
consistent with past studies by Anderson et al which found significant short-term 
improvements in sleep disturbances post-MBSR intervention among breast 
cancer survivors (Anderson et al., 2013), similar to a study by Carlson et al that 
found the beneficial effects of MBSR on subjective sleep duration and efficiency 
among breast cancer and prostate cancer patients (Carlson et al., 2005). 
However, controversy exists with regard to whether the amount of mindfulness 
practiced would predict the extent of improvement. Shapiro et al. found that 
MBSR is indeed a promising intervention to improve sleep quality in breast 
cancer survivors whose sleep complaints are due to stress, but also found that it 
needs to be practiced to have an effect. That is to say, the amount of 
mindfulness practice, as measure in weekly minutes, is associated with 
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improvement in sleep quality measures, and the effects are relatively transient 
(Shapiro et al., 2003). However, the Lengacher study made no much 
observation, possibly due to a relatively short follow-up period or the low average 
rates of mindfulness practice overall. At this moment, a consensus has not been 
reached, but it certainly has important implications for the implementation of 
MBSR treatment in the real world. If motivation is a major predictive factor for the 
outcome of MBSR treatment, the treatment might not be effective if a patient is 
not willing to or have the motivation to commit time to practice mindfulness. This 
condition is generally not covered in a clinical trial since patients were randomly 
assigned into a treatment condition and only results from those considered 
compliant with the intervention routine are included. But in the real world, it might 
suggest a new aspect to consider when screening potential participants for 
MBSR treatment (Lengacher et al., 2011).  
 
Neuroendocrine function (stress hormone) 
 Matousek et al. reviewed the literature related to cortisol changes 
following MBSR intervention and found significant reduction in daily cortisol 
levels in various populations during 12-month follow-up (Matousek et al., 2010). 
He found cortisol to be a reliable biological marker to assess the effectiveness of 
interventions intended to reduce stress, since it is directly linked to adrenocortical 
activity in response to stress and generally responsive to stress-reducing 
interventions. Later Matousek et al. evaluated changes in the cortisol awakening 
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response (CAR) in 33 early stage breast cancer patients who has completed 
medical treatment for cancer and took an 8-week MBSR program (Matousek et 
al., 2011). CAR, a distinct characteristic of HPA axis in response to the natural 
stressor of awakening in the morning, is highly stable in each individual and 
might be blunted following chronic stress (Chida & Steptoe, 2009). Results from 
the study showed that MBSR intervention was positively associated with CAR, 
with the cortisol level showing a significant and prolonged increase after 
awakening during the post-MBSR period.  In participants with the higher CAR at 
the start of the intervention, increase in CAR was accompanied by significant 
reduction in depression level, perceived stress, and medical symptoms. These 
results suggest MBSR is associated with psychological and physiological 
improvements, but the small sample size and lack of a randomized control group 
without MBSR intervention prevents us from drawing solid conclusions.  Plus, 
without a reliable baseline CAR level for reference, the meaning of the changes 
in CAR profile, pre- and post-intervention, cannot be explained without 
speculation. A more comprehensive assessment of other stress markers, 
including DHEAS and immune system markers may be needed to draw a solid 
conclusion about MBSR-related improvements on neuroendocrine functions.  
 
Telomere length and telomerase activity 
 Current research has shown that cellular markers of aging, telomere 
length (TL) and telomerase activity (TA), are in part regulated by chronic 
	  39 
psychological stress, depression, and anxiety, although the mechanism remains 
unclear. Psychological and oxidative stress may lead to shortened telomere 
length and reduced telomerase, and shortened telomeres may further cause 
chromosome instability (Desmaz et al., 2003) and increased risk of developing 
cancer (Fordyce et al., 2005). However, previous studies have demonstrated that 
telomeres are dynamic structures that can be shortened or lengthened 
(Blackburn et al., 1989), and stress-reducing interventions may improve telomere 
length and telomerase activity (Daubenmier et al., 2011). Therefore it is logical to 
hypothesize that beneficial changes initiated by MBSR are partly due to 
restoration of telomere length and telomerase activity, and should there be 
changes in telomere length and telomerase activity, they may correlate with the 
established improvements in psychological outcomes.  
  Lengacher et al. reported findings from the first randomized clinical trial 
that examined the effects of MBSR on TL and TA in breast cancer survivors 
(Lengacher et al., 2014). During a 12-week participant follow-up including 6-
weeks in the MBSR program, TA increased approximately 17% in the MBSR 
group compared to 3% in the usual care group.  
The steady increase in TA over time and significant between-group 
difference suggest a positive post-treatment effect of MBSR on TA. However, no 
evidence showed that MBSR significantly improved TL in the 12 week post-
treatment. Similarly, no association between higher TA and higher mindfulness or 
better psychological outcome was observed. The results with respect to TA 
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increase were promising, but inconclusive with regard to the association between 
MBSR and cellular aging. Especially because telomerase acts by adding 
nucleotide to ends of telomeres, elongation of telomeres is expected if 
telomerase activity increases. It might be due to a short follow-up of 12-weeks, 
since change in telomere length due to behavioral interventions may take at least 
1 year to be evident (Ornish, 2008). It leads to the even more interesting question 
of what is the mechanism linking stress cognition, psychological well-being, and 
aging at the cellular level. One theory suggests that levels of stress hormones 
mediate the process. Epel suggests meditation decreases the levels of stress 
hormones and oxidative stress, and increases the levels of hormones beneficial 
to telomeres and telomerase (Epel et al., 2009). Further randomized clinical trials 
should examine the effect of MBSR on longer time frame in order to assess 
telomere length. 
 
Immune function  
 One of the first studies to assess the effects of participation in MBSR on 
immune function was done by Carlson and colleagues in 2007 (Carlson et al., 
2007), in which they assessed the cell counts of lymphocytes and productions of 
cytokines. Within the lymphocyte subtypes (NK cells, B cells and T cells) showed 
no significant change over the course of 1-year follow up. However, pro-
inflammatory cytokines, including INF-gamma, TNF alpha, IL-4, and IL-10, 
decreased continuously over 1 year. Pro-inflammatory cytokines have been 
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linked with increased self-reported stress symptoms and mood disturbance 
(Audet et al., 2014), so the results were consistent with the hypothesis that 
MBSR reduces stress symptoms. However, this study lacked a control group and 
included a sample of mixed gender and heterogeneous types of cancer. The 
results should be analyzed and reported separately to draw a conclusion about 
MBSR and breast cancer recovery alone because these factors may predict a 
different response to the intervention.  
 Witek-Janusek et al. investigated the effects of MBSR on immune function 
in breast cancer patients alone (Witek-Janusek et al., 2008). Their investigation 
used a non-randomized study design where early stage breast cancer patients 
self-selected into an 8-week MBSR program or into a control group with 
assessment only. Outcomes, including immune function, quality of life, and 
cortisol level were assessed from at least 10 days after surgery to 4-weeks after 
MBSR completion. At the first assessment, the baseline assessments for both 
groups showed immune dysfunction characterized by a general reduction in NK 
cell activity and IFN-gamma production, and an increase in pro-inflammatory 
cytokines IL-4, IL-6 and IL-10 production. However over time, the MBSR group 
showed significant restoration of NK cell activity and IFN-gamma production, with 
a decrease in IL-4, IL-6, and IL-10 production. Women in non-MBSR group 
continued to show immune dysregulation. A similar restoration of cortisol was 
seen in MBSR group compared to non-MBSR group. However the conclusions 
from this study are limited because participants were not randomly assigned to 
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the MBSR or usual care group. Self-selection may reflect selection bias since 
participants who chose the MBSR group might have preconceptions or 
expectation for the MBSR program and that might influence their stress level, 
quality of life, and indirectly influence their objective stress parameters and 
immune function.  
 To study immune function after breast cancer treatment and MBSR with a 
most strictly controlled design, Lengacher et al. did a randomized clinical trial 
with 82 participants newly diagnosed with stage O-III breast cancer and randomly 
assign them into a 6-week MBSR intervention or a control group (Lengacher et 
al., 2013). Assessments were made at baseline, 6-weeks, at MBSR completion 
and 6-week follow up. They found that between the baseline and 6-week period, 
cell counts for lymphocytes increased by a similar extent in both groups, 
suggesting a natural history of lymphocyte recovery after completion of 
conventional breast cancer treatment, and the recovery appears to be 
independent of MBSR practice. However in the 6-week follow up, a significant 
increase in lymphocyte subset (PHA-induced T cell activation) and restoration of 
cytokines was seen in patients enrolled in MBSR program compared to usual 
care group. The conclusion is that MBSR confers positive effects on immune 
recovery following breast cancer treatment, but only at a time when patients are 
further removed from cancer treatment and immune depression. The mechanism 
of how MBSR facilitates immune recovery is still unclear. It was hypothesized 
that MBSR is likely to reduce the activation of stress-induced neuroendocrine 
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system and lower levels of stress hormones including glucocorticoids and 
catecholamines, which are responsible for the dysregulation of cytokines. To 
confirm that, further measurements on cortisol level along with immune recovery 
are required.  	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DISCUSSION 	  
 Breast cancer is the most common type of cancer and second leading 
cause of cancer death among women in the United States. Approximately 
231,840 of new cases will occur in 2015 and an estimate of 2.8 million women is 
living with breast cancer. In contrast with the increasing incidence and 
prevalence of breast cancer, due to early detection and advances in treatment, 
the 5-year survival rate for women diagnosed with breast cancer is increasing at 
a steady rate. This trend results in an increasing number of women living with or 
beyond treatment and at some point may be challenged to overcome the 
possible adverse effects resulting from cancer diagnosis or treatment on their 
daily life. Studies have shown that patients going through the continuum of 
cancer management, from the early diagnostic phase, to cancer treatment, and 
post-treatment survival, are all likely to exhibit symptoms of psychological and 
immunological disturbances of varying severity. The prevalence is exceptionally 
high in women with breast cancer even compared to patients with other cancer 
types, with approximately one in every three breast cancer patients experiencing 
psychological problems such as stress and related depression, anxiety, fatigue, 
and fear of recurrence. Untreated psychological disturbance may have huge 
negative impact on disease progression and recurrence, lower the survivor’s 
quality of life, hinder their transition to post-treatment life, and decrease their 
ability to cope with illness. Consequently it is of great importance to promote 
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approaches that can help patients reduce cancer-related stress and make them 
essential components of cancer care besides conventional therapy. 
  MBSR is a form of CAM therapy that has been used by some cancer 
patients for self-regulation of stress. Rooted in the ancient teachings of Buddhist 
tradition and adapted by Dr. Kabat-Zinn into an 8-week course, MBSR program’s 
goal is to teach patients to take an active role in stress management. It 
encourages patients to keenly observe and be more aware of their surroundings, 
monitor their inner emotions and changes in body sensations, and at the same 
time maintain an open, nonjudgmental, and non-interpretive perspective. In 
general, MBSR enhances attention and awareness, promotes self-regulation, 
and in this way leads to a relaxation state in the body. The 8-week MBSR 
program teaches patients various mindfulness meditation techniques combined 
with group activities and at home practices to achieve this goal.  
 The increasing popularity of MBSR as an alternative therapy to cancer 
calls for the necessity to conduct research in this field to determine whether it 
really helps reduce stress in cancer patients. The distinctive characteristics of 
women with breast cancer make them the ideal group of patients to start with 
because 1) breast cancer is a specific clinical condition and responses may 
different from patients with other oncology, and 2) women with breast cancer are 
particularly susceptible to cancer-related stress symptoms. Since 2000, there 
were several studies on the effects of MBSR on breast cancer patients. Most of 
them focused only on psychological outcomes. Using different measures 
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including Perceived Stress Scale, depression scales and others, they 
unanimously reported improvement in stress, depression, mood disturbance, fear 
of recurrence, and quality of life in breast cancer patients practicing MBSR 
(Dobkin, 2008; Lengacher et al., 2009; Shapiro et a., 2003; Tacon et al., 2005; 
Lengacher et al., 2014). Some studies reported improvement in subject and 
objective sleep pattern and quality as well (Lengacher et al., 2015; Shapiro et al., 
2003). Only a few studies assess the effects of MBSR on biologic outcomes in 
breast cancer patients. Two studies reported MBSR has positive effects on the 
recovery of counts and activity of lymphocytes and cytokine production 
(Lengacher et al., 2013; Witek-Janusek et al., 2008). One study reported MBSR’s 
effect in lowering cortisol and normalizing CAR (Matousek et al., 2011). Another 
study reported MBSR restores telomerase activity even in a short follow-up 
period (Lengacher et al., 2014). These results are all consistent with a more 
balanced, healthy immune system and reduced activation of the stress response 
system, HAP and SAM axis.  
 But these results should be interpreted with caution, since the studies are 
all of limited study design. The Matousek study on cortisol level compares the 
pre- and post- MBSR outcomes without a control group, making the interpretation 
of results ambiguous. The Witek-Janusek study used a nonrandomized control 
group, which is subject to selection bias. The only studies that assess the effects 
of MBSR on homogenous breast cancer women only with a randomized control 
design are those by Lengacher et al. Their results show that the trend is in favor 
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of MBSR’s positive clinical effects on psychological and biological outcomes, 
although it needs to expand the follow up time window to see effects on telomere 
length, cortisol level and a few other biologic outcomes. As preliminary studies, 
they certainly yield results that warrant conducting further studies to validate.  
 From current results, there is controversy with regards to whether time in 
practice MBSR and class attendance is correlated with an increase in 
mindfulness and improvement in measured outcomes. The two studies by 
Carlson and Speca which include pre- and post-intervention assessment of the 
same sample of whom 43% were breast cancer female survivors found that more 
number of minutes in practice and the number of session attended is positively 
associated with a greater magnitude of improvement in mood disturbance and 
stress symptoms. Similarly, Shapiro et al. reported participants in the MBSR 
group who engaged in more mindfulness practice had greater improvements in 
sleep quality. In contrast, Lengacher et al. found no such association between 
total minutes of MBSR practice and positive changes in psychological outcomes 
and quality of life. Arguments could be made for both sides. From one 
perspective, mindfulness is a state of mind that, just as it came from the tradition 
of Buddhist monks who make it an everyday routine, needs continuous effort to 
maintain and sustain. Therefore the observation that time engaged in practice 
being associated with improvement in outcomes serves as direct evidence that 
MBSR is the main driving force for stress reduction. But from the other 
perspective, it could be that once the teachings and concepts of mindfulness, 
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including an attitude of non-judging and acceptance, is instilled through MBSR, 
its beneficial results are self-sustaining and do not need further formal practice to 
maintain. Another possibility is that a particular component of the MBSR 
program, mindfulness meditation, mindfulness yoga, or supportive group 
discussion, is the most effective in reducing stress. Further research is needed to 
determine which theory is correct.  
 Based on current studies, people have noticed the possibility of predicting 
the success of MBSR using baseline biomarkers obtained at the start of the 
study (Reich et al., 2014). Targeting which breast cancer patients would benefit 
more from the program has important implications for its application to a broader 
population, especially if MBSR needs continuous practice and motivation on 
patients’ part to be effective. Targeting a certain group of people who are likely to 
respond to this treatment will lead to higher cost-effectiveness, greater success, 
and and a reduction in time and energy wasted by patients.  Lengacher et al. 
found that different baseline immune biomarkers were associated with 
improvement in different symptom clusters, including psychological stress 
symptoms, gastrointestinal-related symptoms, and cancer-related fatigue and 
sleep disturbance (Lengacher et al., 2011). It appears that women with an 
increased baseline immune activity experience greater improvements in all these 
symptoms compared to women with weaker baseline immune activity after 
MBSR program. However due to the small sample size, further studies are 
needed to validate the predictive value of these immune biomarkers on MBSR 
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outcome, and test if these biomarkers can be generalized to a broader 
population. If the results are validated, they will also have important implications 
on the optimal application time window of MBSR program for breast cancer 
patients and survivors.  
 MBSR are currently offered in healthcare settings around the world for 
patients with different backgrounds. Preliminary clinical studies show promising 
outcomes with regards to MBSR’s beneficial effects on reducing subjective 
perceived stress, depression and mood disturbances, and increasing quality of 
life and sleep pattern in breast cancer patients. Although the trend is in support of 
MBSR, more data from controlled randomized clinical studies are necessary in 
order to draw a reliable conclusion on its effectiveness in reducing stress through 
measurements of objective stress markers and immune functions. Since MBSR 
costs relatively less and shows some positive effects, it will not be harmful to 
implement MBSR more widely in breast cancer patients as a complementary 
therapy. However, to fully understand its value, concept, application and benefits, 
a more comprehensive understanding on its mechanism of action, including how 
MBSR initiates changes in the immune system and stress-triggered activation of 
neuroendocrine system, is of great importance.   
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